Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBITDA (2019 - 2025)

Historic EBITDA for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$41.1 million.

  • Allogene Therapeutics' EBITDA rose 3708.31% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.9 million, marking a year-over-year increase of 2454.03%. This contributed to the annual value of -$256.7 million for FY2024, which is 1934.38% up from last year.
  • As of Q3 2025, Allogene Therapeutics' EBITDA stood at -$41.1 million, which was up 3708.31% from -$51.0 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' EBITDA registered a high of -$2.1 million during Q4 2021, and its lowest value of -$96.0 million during Q1 2023.
  • Moreover, its 5-year median value for EBITDA was -$66.2 million (2024), whereas its average is -$66.3 million.
  • In the last 5 years, Allogene Therapeutics' EBITDA skyrocketed by 9846.18% in 2021 and then crashed by 442438.79% in 2022.
  • Quarter analysis of 5 years shows Allogene Therapeutics' EBITDA stood at -$2.1 million in 2021, then plummeted by 4424.39% to -$94.2 million in 2022, then increased by 10.53% to -$84.3 million in 2023, then rose by 28.62% to -$60.2 million in 2024, then surged by 31.68% to -$41.1 million in 2025.
  • Its last three reported values are -$41.1 million in Q3 2025, -$51.0 million for Q2 2025, and -$59.6 million during Q1 2025.